Nautilus Biotechnology logo
NAUTNautilus Biotechnology
Trade NAUT now
Nautilus Biotechnology primary media

About Nautilus Biotechnology

Nautilus Biotechnology (NASDAQ:NAUT) specializes in harnessing advanced scientific techniques to enhance the understanding of human biology. At the heart of its operations, Nautilus aims to revolutionize the field of proteomics through its pioneering platform, designed to deliver an unprecedented scale of protein analysis. This endeavor is not just about pushing the boundaries of scientific research; it's about unlocking new pathways for disease treatment and diagnostics, thereby opening up possibilities that were previously deemed unachievable. As Nautilus navigates through complex biological landscapes, its primary objective remains to transform the approach towards drug development and personalized medicine, ensuring that the future of healthcare is more precise, effective, and accessible.

What is NAUT known for?

Snapshot

Public US
Ownership
2016
Year founded
167
Employees
Seattle, United States
Head office
Loading Map...

Operations

All Locations
Seattle, US

Produtos e/ou serviços de Nautilus Biotechnology

  • Development of a next-generation protein analysis platform aiming at a broader, more nuanced understanding of the human proteome.
  • Collaboration projects with pharmaceutical and research institutions to leverage their platform for drug discovery and biomarker identification.
  • Offering an end-to-end service for protein quantification and analysis, aiming at improving the speed and accuracy compared to existing technologies.
  • Investment in AI and machine learning technologies to enhance the data analysis capabilities of their proteomics platform.
  • Partnerships for developing diagnostic tools based on proteomic insights for various diseases.
  • Engaging in scientific studies and publishing research findings to contribute to the broader scientific community’s understanding of proteomics.

equipe executiva do Nautilus Biotechnology

  • Mr. Sujal M. PatelCo-Founder, CEO, President, Secretary & Director
  • Dr. Parag Mallick Ph.D.Co-Founder, Chief Scientist & Director
  • Mr. Kentaro SuzukiChief Marketing Officer
  • Ms. Anna MowryCFO & Treasurer
  • Mr. Matthew B. Murphy ESQ.General Counsel
  • Ms. Gwen E. WeldChief People Officer
  • Dr. Subra Sankar Ph.D.Senior Vice President of Product Development

Conecte-se conosco

A Grafa não é um consultor financeiro. Você deve buscar aconselhamento independente, jurídico, financeiro, tributário ou de outra natureza que se relacione às suas circunstâncias únicas.

A Grafa não se responsabiliza por qualquer perda causada, seja por negligência ou de outra forma, decorrente do uso ou da confiança nas informações fornecidas direta ou indiretamente pelo uso desta plataforma.